Profits rise 20% at Irish arm of Regeneron

Bulk manufacturing at the company's facility in Limerick “was temporarily interrupted due to unanticipated facility repairs” this year
The accounts show that tax reforms delivered $120m in additional corporation tax from Regeneron Ireland last year.

The accounts show that tax reforms delivered $120m in additional corporation tax from Regeneron Ireland last year.

Pre-tax profits at the main Irish arm of biotechnology giant, Regeneron last year increased by 20 per cent to $4.91bn (€3.8bn).

New accounts filed by Regeneron Ireland DAC show that the firm increased its profits as revenues rose by 3 per cent from $12.15bn to $12.53bn in 2025.

The company - which operates a large manufacturing plant in Limerick - is one of the largest contributors of corporation tax amongst US multinationals operating here and its corporation tax charge last year totalled $716.6m resulting in post tax profits of $4.19bn.

The accounts show that Pillar Two international tax reforms aimed at increasing the corporate tax take from large firms delivered $120m in additional corporation tax from Regeneron Ireland last year which resulted in the overall corporation tax charge of $716.6m.

The firm last year paid out dividends of $5.3bn to immediate parent, Regeneron International Holdings (RIH) LLC and a note states that in March of this year the company paid further dividends of $1.5bn to RIH LLC.

In another post balance sheet event, a note states that during the first half of 2026, bulk manufacturing production at the company's facility in Limerick “was temporarily interrupted due to unanticipated facility repairs that commenced during the first quarter of 2026”.

The note states that as of June 2026, manufacturing production had recommenced.

The revenues recorded by the Irish based unit account for 87.6 per cent of Regeneron’s global revenues of $14.3bn in 2025.

Regeneron’s Irish workforce is split between Dublin and Limerick locations with its Limerick operation at the former Dell site employing the bulk of its employees.

Regeneron DAC develops, manufactures and commercialises drugs for the treatment of serious medical conditions and acts as an intermediary treasury centre for certain subsidiaries of Regeneron Pharmaceuticals Inc.

Profits were last year hit by a Research & Development (R&D) spend of $1.09bn.

Revenues were mainly made up of collaboration revenues of $8.14bn and intercompany revenues of $4.19bn.

Numbers employed at Regeneron Ireland DAC last year increased from 2,082 to 2,163 made up of 1,956 in production, 75 in R&D, 118 in administration and 14 in commercial.

The company’s staff costs last year increased from €317m to $349.54m that included share based payments of $64.4m.

The profit takes account of $676.2m in non-cash amortisation costs and non-cash depreciation costs of $92.4m.

Pay to directors increased from $1.66m to $1.88m.

Shareholder funds totalled $6.19bn that included accumulated profits of $1.9bn.

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited